Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study

Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study

ABSTRACT In vitro data suggest the monoclonal antibody sotrovimab may have lost inhibitory capability against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant. We aimed to provide real-life data on clinical outcomes in hospitalized patients. We retrospectively analyze...

Full description

Bibliographic Details
Main Authors: Marcel S. Woo, Thomas Theo Brehm, Marlene Fischer, Andreas Heyer, Dominic Wichmann, Sabine Jordan, Dominik Nörz, Marc Lütgehetmann, Marylyn M. Addo, Ansgar W. Lohse, Stefan Schmiedel, Stefan Kluge, Julian Schulze zur Wiesch
Format: Article
Language:English
Published: American Society for Microbiology 2023-02-01
Series:Microbiology Spectrum
Subjects:
SARS-CoV-2
COVID-19
Omicron
sotrovimab
remdesivir
monoclonal antibodies
Online Access:https://journals.asm.org/doi/10.1128/spectrum.04103-22

Similar Items

Similar Items